Compare Mesoblast Limited (MESO) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs STMicroelectronics NV — how do they compare? Mesoblast Limited trades at $14.25 (market cap $1.75B), while STMicroelectronics NV trades at $52.1 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 27.5× Mesoblast Limited's market cap, and STMicroelectronics NV pays a 0.68% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and STMicroelectronics NV for 64 Days on average.
| MESO | STM | |
|---|---|---|
Market Cap | $1.75B | $48.14B |
Volume | 239,027 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $20.96 | $79.91 |
52-Week Low | $13.19 | $21.20 |
Typical Hold Time | 15 Days | 64 Days |
Enterprise Value | $1.83B | $45.66B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
STM (STMicroelectronics) trades at $51.88, down 7.65% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 101.49 and negative net income margin of -0.39%, though Q2 2026 EPS beat expectations. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2 billion by 2027. Cash flow improved in 2025 with net cash flow of $555 million, while the balance sheet remains solid with total assets of $24.74 billion.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings (51.72%) and a $77.31 price target, implying significant upside. Key risks include earnings volatility, competitive pressures in semiconductors, and macroeconomic headwinds. Near-term performance hinges on execution of AI and automotive growth initiatives, with Q3 2026 earnings as a critical catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
